RET and non-small cell lung carcinoma: Currently, the treatment of advanced NSCLC relies on molecular testing for predictive biomarkers, including oncogenic drivers, to determine eligibility for targeted therapies such as those for EGFR, ALK, ROS1, BRAF, HER2, MET, RET, or KRASG12C.